Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Total Liabilities (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Total Liabilities for 4 consecutive years, with $66.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 16.71% to $66.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $66.7 million, a 16.71% decrease, with the full-year FY2025 number at $66.7 million, down 16.71% from a year prior.
  • Total Liabilities was $66.7 million for Q4 2025 at Day One Biopharmaceuticals, up from $62.9 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $93.7 million in Q2 2024 to a low of $8.2 million in Q1 2022.
  • A 4-year average of $40.7 million and a median of $29.7 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: skyrocketed 279.35% in 2024, then plummeted 37.89% in 2025.
  • Day One Biopharmaceuticals' Total Liabilities stood at $17.0 million in 2022, then surged by 73.34% to $29.5 million in 2023, then surged by 171.24% to $80.0 million in 2024, then decreased by 16.71% to $66.7 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Total Liabilities are $66.7 million (Q4 2025), $62.9 million (Q3 2025), and $58.2 million (Q2 2025).